Abiomed - ABMD Stock Forecast, Price & News

Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides a continuum of care to heart failure patients. The company offers Impella 2.5, a percutaneous micro heart pump with integrated motor and sensors; and Impella CP, a device for use by interventional cardiologists to support patients in the cath lab, as well as by cardiac surgeons in the heart surgery suite. It also provides Impella 5.0, Impella LD, and Impella 5.5, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; Impella RP, a percutaneous catheter-based axial flow pump; Impella SmartAssist platform that includes optical sensor technology for improved pump positioning and the use of algorithms that enable improved native heart assessment during the weaning process; Impella Connect, a cloud-based technology that enables secure and remote viewing of the automated impella controller for physicians and hospital staffs; and OXY-1 System, a portable external respiratory assistance device. In addition, the company is developing Impella ECP, a pump for blood flow of greater than three liters per minute; Impella XR Sheath, a sheath that expands and recoils allowing small bore access and closure with Impella heart pumps; Impella BTR, a percutaneous micro heart pump with integrated motors and sensors; and preCARDIA, a catheter-mounted superior vena cava therapy system designed to rapidly treat acutely decompensated heart failure. Abiomed, Inc. sells its products through direct sales and clinical support personnel in the Germany, France, United States, Japan, Europe, Canada, Latin America, the Asia-Pacific, and the Middle East. The company was founded in 1981 and is headquartered in Danvers, Massachusetts.

Analysts Set New Price Targets

ABMD has been the topic of a number of recent analyst reports. Morgan Stanley lowered their target price on shares of Abiomed from $275.00 to $235.00 and set an "underweight" rating on the stock in a research note on Friday, July 15th. StockNews.com lowered shares of Abiomed from a "buy" rating to a "hold" rating in a research report on Friday, July 1st. Finally, Deutsche Bank Aktiengesellschaft lowered their price target on Abiomed from $410.00 to $355.00 in a research report on Thursday, July 21st.

Abiomed Stock Performance

Shares of Abiomed stock opened at $291.50 on Monday. The stock has a market capitalization of $13.30 billion, a price-to-earnings ratio of 61.50 and a beta of 1.35. The company has a fifty day moving average of $262.33 and a 200-day moving average of $282.98. Abiomed has a 52-week low of $219.85 and a 52-week high of $379.30.

Abiomed (NASDAQ:ABMD - Get Rating) last released its earnings results on Thursday, August 4th. The medical equipment provider reported $1.25 earnings per share for the quarter, beating analysts' consensus estimates of $1.06 by $0.19. The company had revenue of $277.15 million during the quarter, compared to analyst estimates of $276.46 million. Abiomed had a return on equity of 14.33% and a net margin of 20.60%. Abiomed's revenue for the quarter was up 9.7% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.10 EPS. On average, equities research analysts forecast that Abiomed will post 4.7 earnings per share for the current fiscal year.

Insider Activity

In related news, Director Martin P. Sutter sold 2,000 shares of the company's stock in a transaction on Tuesday, May 17th. The shares were sold at an average price of $258.01, for a total transaction of $516,020.00. Following the completion of the sale, the director now directly owns 128,390 shares in the company, valued at approximately $33,125,903.90. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other news, CFO Todd A. Trapp sold 1,000 shares of the firm's stock in a transaction dated Wednesday, August 3rd. The shares were sold at an average price of $300.00, for a total value of $300,000.00. Following the completion of the sale, the chief financial officer now directly owns 16,927 shares of the company's stock, valued at approximately $5,078,100. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Martin P. Sutter sold 2,000 shares of Abiomed stock in a transaction dated Tuesday, May 17th. The shares were sold at an average price of $258.01, for a total transaction of $516,020.00. Following the sale, the director now directly owns 128,390 shares in the company, valued at approximately $33,125,903.90. The disclosure for this sale can be found here. Insiders own 2.50% of the company's stock.